で公開中です！詳しく見る

NIKI

Niki BioSolutions

NIKI

時価総額 $165万

2.03 USD

-0.19

8.56%

終値時点更新済み 10月16日 16:00 EDT

1日

-8.56%

5日間

-47.14%

1か月

-57.44%

3か月

-77.01%

6か月

-77.01%

年初来

-77.01%

1年

-77.01%

5年間

-77.01%

10年間

-77.01%

概要： Niki BioSolutions Inc, formerly Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA).

従業員数： 2

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series

Company's blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome

Niki BioSolutions' Rett Syndrome Biomarker Program Featured in the International Rett Syndrome Foundation's “Rett Research Tool Belt” Series

ニュートラル

Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002

Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer's biomarker cohort PRINCETON, N.J., and NEW HAVEN, Conn.

Niki BioSolutions Partners with Global Alzheimer's Platform Foundation to Deliver Plasma-Based APOE Genotyping for Bio-Hermes-002

ニュートラル

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomarker testing solutions, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Niki BioSolutions to Participate in the Lytham Partners Fall 2026 Investor Conference

ニュートラル

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform

Niki BioSolutions Accelerates Its Alzheimer's Disease Testing Pipeline Through Strategic Bioinformatics and Statistical Analysis Partnership with Fios Genomics

ニュートラル

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

NEW HAVEN, CT and PRINCETON, NJ, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ: NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and biomarker testing solutions, today announced that it will participate in the 28th Annual H.C. Wainwright Global Investment Conference, taking place September 14 through September 16, 2026, at the Lotte New York Palace Hotel in New York City.

Niki BioSolutions to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています